X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
1. Bibr 1048
2. Dabigatran
3. Dabigatran Etexilate
4. Dabigatran Etexilate Mesylate
5. Etexilate Mesylate, Dabigatran
6. Etexilate, Dabigatran
7. Mesylate, Dabigatran Etexilate
8. N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1h-benzimidazol-5-yl)carbonyl)-n-2-pyridinyl-beta-alanine
9. Pradaxa
1. Dabigatran Etexilate Mesylate
2. 872728-81-9
3. Pradaxa
4. Ethyl 3-[[2-[[4-[(z)-n'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate;methanesulfonic Acid
5. Dtxsid20236248
6. Ex-a1966
7. Mfcd25424070
8. S5960
9. Ccg-213236
10. Cs-w004358
11. (z)-ethyl 3-(2-(((4-(n'-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-n-(pyridin-2-yl)-1h-benzo[d]imidazole-5-carboxamido)propanoate Methanesulfonate
12. 728p819
| Molecular Weight | 723.8 g/mol |
|---|---|
| Molecular Formula | C35H45N7O8S |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 17 |
| Exact Mass | 723.30503259 g/mol |
| Monoisotopic Mass | 723.30503259 g/mol |
| Topological Polar Surface Area | 217 Ų |
| Heavy Atom Count | 51 |
| Formal Charge | 0 |
| Complexity | 1100 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Pradaxa |
| PubMed Health | Dabigatran (By mouth) |
| Drug Classes | Anticoagulant |
| Drug Label | The chemical name for dabigatran etexilate mesylate, a direct thrombin inhibitor, is -Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl] phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester, methanesulfo... |
| Active Ingredient | Dabigatran etexilate mesylate |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | eq 150mg base; eq 75mg base |
| Market Status | Prescription |
| Company | Boehringer Ingelheim |
| 2 of 2 | |
|---|---|
| Drug Name | Pradaxa |
| PubMed Health | Dabigatran (By mouth) |
| Drug Classes | Anticoagulant |
| Drug Label | The chemical name for dabigatran etexilate mesylate, a direct thrombin inhibitor, is -Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl] phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester, methanesulfo... |
| Active Ingredient | Dabigatran etexilate mesylate |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | eq 150mg base; eq 75mg base |
| Market Status | Prescription |
| Company | Boehringer Ingelheim |
Pradaxa 75 mg
- Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.
Pradaxa 110 mg
- Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age 75 years; heart failure (NYHA Class II); diabetes mellitus; hypertension.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
Pradaxa 150 mg
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age 75 years; heart failure (NYHA Class II); diabetes mellitus; hypertension.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
Antithrombins
Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins. (See all compounds classified as Antithrombins.)
B01AE07
Market Place
